All In Biotech

Drug Trial Radar · NCT01085812

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Jan 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 734 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

734

Actual

Start

Mar 2010

Primary completion

Oct 2011

Study completion Oct 2011

Sponsor

Lead sponsor
Forest LaboratoriesAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 12, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).

Conditions

  • Depression
  • Major Depressive Disorder

Interventions

  • Levomilnacipran ERDrug

    Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.

  • PlaceboDrug

    Matching placebo to be given orally, in capsule form, once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Relapse (Days)Time frame: 24 Weeks

Locations

35 sites in 2 countries. Site status is shown where the registry gives one.

  • Forest Investigative Site #023

    Beverly Hills, California

  • Forest Investigative Site #017

    Encino, California

  • Forest Investigative Site #021

    Garden Grove, California

  • Forest Investigative Site #025

    Newport Beach, California

  • Forest Investigative Site #030

    Orange, California

  • Forest Investigative Site #002

    San Diego, California

  • Forest Investigative Site #003

    Sherman Oaks, California

  • Forest Research Institute #001

    Bonita Springs, Florida

  • Forest Investigative Site #015

    Fort Myers, Florida

  • Forest Investigative Site #029

    Maitland, Florida

  • Forest Investigative Site #005

    North Miami, Florida

  • Forest Investigative Site #016

    Orlando, Florida

  • Forest Investigative Site #004

    South Miami, Florida

  • Forest Investigative Site #014

    Atlanta, Georgia

  • Forest Investigative Site #022

    Chicago, Illinois

  • Forest Investigative Site #006

    Chicago, Illinois

  • Forest Investigative Site #009

    Prairie Village, Kansas

  • Forest Investigative Site #013

    Baltimore, Maryland

  • Forest Investigative Site #010

    Boston, Massachusetts

  • Forest Investigative Site #012

    St Louis, Missouri

  • Forest Investigative Site #011

    Staten Island, New York

  • Forest Investigative Site #026

    Portland, Oregon

  • Forest Investigative Site #008

    Bridgeville, Pennsylvania

  • Forest Investigative Site #028

    Norristown, Pennsylvania

  • Forest Investigative Site #020

    Philadelphia, Pennsylvania

  • Forest Investigative Site #024

    Memphis, Tennessee

  • Forest Investigative Site #007

    Dallas, Texas

  • Forest Investigative Site #019

    San Antonio, Texas

  • Forest Investigative Site #018

    Bellevue, Washington

  • Forest Investigative Site #027

    Seattle, Washington

  • Forest Investigative Site #050

    Kelowna, British Columbia, Canada

  • Forest Investigative Site #051

    Vancouver, British Columbia, Canada

  • Forest Investigative Site #052

    Sydney, Nova Scotia, Canada

  • Forest Investigative Site #055

    Chatham, Ontario, Canada

  • Forest Investigative Site #053

    Ottawa, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.